News
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced data from preclinical studies of three exatecan-based ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback